Novo Nordisk A/S
F:NOVC
Relative Value
The Relative Value of one
NOVC
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 90.7 EUR,
Novo Nordisk A/S
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
NOVC Competitors Multiples
Novo Nordisk A/S Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Novo Nordisk A/S
F:NOVC
|
1.1T EUR | 3.5 | 10.4 | 7.7 | 9.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD | 15.2 | 48 | 32.4 | 34.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
593.2B USD | 6.3 | 22 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
294.8B CHF | 4.8 | 31.4 | 13.2 | 15.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP | 5.4 | 31.2 | 17.3 | 24.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.7B CHF | 5.7 | 22.9 | 14.1 | 18.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
310.9B USD | 4.7 | 16.9 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.8B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.9B USD | 2.6 | 17.7 | 7.4 | 9.1 | |
| UK |
|
GSK plc
XETRA:GS71
|
102.8B EUR | 2.7 | 15.7 | 7.9 | 11.3 |